Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.72 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.71 |
| ▸ | HTR2C | P28335 | 4/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8961172 | 0.88 | MTNR1A (0.72) | MTNR1AMTNR1B | |
| SCHEMBL30448726 | 0.87 | MTNR1A (0.72) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL29032146 | 0.87 | MTNR1A (0.72) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL30449310 | 0.86 | MTNR1A (0.71) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8070269 | 0.86 | MTNR1A (0.71) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL6248768 | 0.86 | MTNR1A (0.80) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8608340 | 0.86 | MTNR1A (0.71) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL30449202 | 0.86 | MTNR1A (0.71) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL5929491 | 0.86 | MTNR1A (0.71) | MTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8609306 | 0.85 | MTNR1A (0.72) | MTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5591775-A | SLEEP DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-01-07 | — | — | US | claimed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | SUZUKI YASUYUKI (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-1206943-B1 | MATRIX ADHERING TO NASAL MUCOSA | TAKEDA PHARMACEUTICAL (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7608737-B2 | Naphthyl(ethyl)acetamides | Concert Pharmaceuticasl Inc. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608737-B2 | Naphthyl(ethyl)acetamides | Concert Pharmaceuticasl Inc. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090264521-A1 | Percutaneous absorption preparation | SUZUKI YASUYUKI | 2009-10-22 | — | — | US | disclosed |
| WO-2008083204-A2 | MODULATION OF NEUROGENESIS BY MELATONINERGIC LIGANDS | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| EP-0919541-B1 | Naphthalene compounds, process for their preparation and their pharmaceutical compositions | SERVIER LAB (FR) | 2005-08-10 | — | — | EP | disclosed |
| US-6143789-A | ENANTIOMORPHS | ADIR ET COMPAGNIE (FR) | 2000-11-07 | — | — | US | disclosed |
| EP-0919541-A1 | Naphthalene compounds, process for their preparation and their pharmaceutical compositions | ADIR ET COMPAGNIE (FR) | 1999-06-02 | — | — | EP | disclosed |
| EP-0662471-B1 | Naphthalene derivatives with affinity to the receptors of melatonine, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1998-03-11 | — | — | EP | disclosed |
| US-5591775-A | SLEEP DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-01-07 | — | — | US | disclosed |
| US-5552418-A | FOR TREATING DISORDERS OF THE MELATONINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1996-09-03 | — | — | US | disclosed |
| EP-0662471-A2 | Naphthalene derivatives with affinity to the receptors of melatonine, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264521-A1 | Percutaneous absorption preparation | MTNR1A, MTNR1B, NPSR1 | MTNR1A 1/4885MTNR1B 2/4885HTR2C 277/4885 |
| US-20120309823-A1 | PERCUTANEOUS ABSORPTION PREPARATIONS | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885HTR2C 248/4885 |
| US-20100004340-A1 | NAPHTHYL(ETHYL) ACETAMIDES | AANAT, MTNR1A, TPH2 | MTNR1A 2/4885MTNR1B 5/4885HTR2C 7/4885 |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | MTNR1A, GAP43, DCX | MTNR1A 1/4885MTNR1B 4/4885HTR2C 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.